Guanxin V for coronary artery disease: a randomized controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031694

Enrollment

Unknown

Registered

2020-04-07

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

GXV group:GXV

GMT group:Guideline-recommended medical therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adults. 2. Meet the diagnostic criteria of CAD. 3. Meet the diagnostic criteria of Qi and Yin deficiency and blood stasis.

Exclusion criteria

Exclusion criteria: 1. Continuation of any form of Chinese herbal medicines for 14 days before enrollment. 2. Be allergic to test ingredients or accessories. 3. The pregnant and lactating women and women planning pregnancy for nearly six months. 4. Individuals participating in other clinical trial.

Design outcomes

Primary

Measure	Time frame
Traditional Chinese medicine syndrome score;Heart function;	—

Secondary

Measure	Time frame
NT-pro BNP;LVEF;CO;SV;6MWT;	—

Countries

China

Contacts

Public ContactNing Gu

Nanjing University of Chinese Medicine

jsguning@163.com+86 15181400995

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026